Prostate cancer as a model for tumour immunotherapy

Current status of immunological therapies for prostate cancer

Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model

The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer

A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer

Oncolytic virus therapy for prostate cancer

Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer

Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization

Tumor specific cytotoxicity and telomerase down-regulation in prostate cancer by autologous dendritic cells loaded with whole tumor cell antigens

Promising novel immunotherapies and combinations for prostate cancer